Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
Canada-U.S. team develops promising ‘sharp-shooter’ drug aimed at several cancers
Original Publication Date: June 18, 2013 8:13AM
Publication Updated: January 9, 2025 2:18AM
TORONTO – A Canadian-U.S. team of researchers has developed a new "sharp-shooter" drug they hope will be a breakthrough in treating several types of cancer.
The experimental drug is known for now as CFI-400945 and is a new class of cancer drug that targets a certain enzyme that gives rise to some malignancies.
Those tumours include breast, ovarian, colorectal, pancreatic and prostate cancers.
The researchers have applied to Health Canada and the U.S. FDA to begin testing the drug in patients.
Dr. Tak Mak of the Princess Margaret Cancer Centre in Toronto and Dr. Dennis Slamon of the University of California, Los Angeles, led the teams that developed the drug.
The two world-renowned researchers have spent a decade developing the drug, funded solely by money raised through donations.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
